Patents by Inventor Carlos Zetina-Rocha

Carlos Zetina-Rocha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Solid forms of nilotinib hydrochloride
    Patent number: 9376419
    Abstract: Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: June 28, 2016
    Assignee: Apotex Inc.
    Inventors: Probal Kanti Datta, Carlos Zetina-Rocha, Cameron L. McPhail, Yajun Zhao, Gamini Weeratunga
  • SOLID FORMS OF NILOTINIB HYDROCHLORIDE
    Publication number: 20150274699
    Abstract: Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).
    Type: Application
    Filed: October 15, 2013
    Publication date: October 1, 2015
    Inventors: Probal Kanti Datta, Carlos Zetina-Rocha, Cameron L. McPhail, Yajun Zhao, Gamini Weeratunga
  • Polymorphic forms of Lapatinib ditosylate and processes for their preparation
    Patent number: 8993579
    Abstract: There is provided a crystalline form of Lapatinib, termed APO-I, and methods for making APO-I. There is also provided a crystalline solvate form of Lapatinib, termed APO-II, and methods for making APO-II.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: March 31, 2015
    Assignee: Apotex Pharmachem Inc
    Inventors: Carlos Zetina-Rocha, Eduardo Gustavo Cammisa, Gamini Weeratunga
  • Process for the preparation of lapatinib and its ditosylate salt
    Patent number: 8952154
    Abstract: There is provided processes for preparing Lapatinib and pharmaceutically acceptable salts thereof by the reductive amination of the aldehyde of Formula II by treatment with 2-methanesulphonylethylamine followed by catalytic hydrogenation in the presence of a suitable hydrogenation catalyst.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: February 10, 2015
    Assignee: Apotex Pharmachem Inc.
    Inventors: Mohammed Abdul Raheem, Gamini Weeratunga, Carlos Zetina-Rocha, Eduardo Gustavo Cammisa
  • PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS DITOSYLATE SALT
    Publication number: 20140018535
    Abstract: There is provided processes for preparing Lapatinib and pharmaceutically acceptable salts thereof by the reductive amination of the aldehyde of Formula II by treatment with 2-methanesulphonylethylamine followed by catalytic hydrogenation in the presence of a suitable hydrogenation catalyst.
    Type: Application
    Filed: December 23, 2011
    Publication date: January 16, 2014
    Applicant: APOTEX PHARMACHEM INC.
    Inventors: Mohammed Abdul Raheem, Gamini Weeratunga, Carlos Zetina-Rocha, Eduardo Gustavo Cammisa
  • POLYMORPHIC FORMS OF LAPATINIB DITOSYLATE AND PROCESSES FOR THEIR PREPARATION
    Publication number: 20130123497
    Abstract: There is provided a crystalline form of Lapatinib, termed APO-I, and methods for making APO-I. There is also provided a crystalline solvate form of Lapatinib, termed APO-II, and methods for making APO-II.
    Type: Application
    Filed: April 21, 2011
    Publication date: May 16, 2013
    Applicant: APOTEX PHARMACHEM INC.
    Inventors: Carlos Zetina-Rocha, Eduardo Gustavo Cammisa, Gamini Weeratunga
  • Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same
    Patent number: 7939662
    Abstract: The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and preparations thereof.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: May 10, 2011
    Assignee: Apotex Pharmachem Inc.
    Inventors: Carlos Zetina-Rocha, Allan W. Rey, Matthew A. Buck, Lotfi Derdour, Stephen E. Horne, Keshava K. S. Murthy
  • Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same
    Publication number: 20090030204
    Abstract: The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and preparations thereof.
    Type: Application
    Filed: December 6, 2007
    Publication date: January 29, 2009
    Inventors: Carlos Zetina-Rocha, Allan W. Rey, Matthew A. Buck, Lotfi Derdour, Stephen E. Horne, K.S. Keshava Murthy
  • Process for the Preparation of Ziprasidone (5-[2-[4-(1,2-Benziosothiazol-3-Y1)-1-Piperazinyl]Ethyl]-6-Chloro-1,3-Dihydro-2H-Indol-2- One
    Publication number: 20070265447
    Abstract: The present invention provides a new and useful process for preparing 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3dihydro-2H-indol-2-one (ziprasidone) and methods for its purification. The process comprises the steps of: (i) mixing 6-chloro-5-(2-chloroethyl)-1,3-dihydro-2H-indol-2-one with either a free base or salt form of 3-(1-piperazinyl)-1,2-benzoisothiazole, in the presence of an alkaline compound and a high-boiling polar organic solvent or mixture of high boiling polar organic solvents, (ii) heating the mixture and stirring for a sufficient amount of time to obtain ziprasidone formation, (iii) cooling the mixture, adding it to water and filtering off the product, (iv) adding water to the product and stirring the suspension, and (v) isolating crude ziprasidone.
    Type: Application
    Filed: November 4, 2005
    Publication date: November 15, 2007
    Inventors: Carlos Zetina-Rocha, Allan Rey, Stephen Horne, Matthew Buck
  • Preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride (ziprasidone hydrochloride)
    Patent number: 7087611
    Abstract: The present invention relates to new and useful processes for the preparation of the anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: August 8, 2006
    Assignee: Apotex Pharmachem Inc.
    Inventors: Carlos Zetina-Rocha, Allan W. Rey, Stephen E. Horne
  • Preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride (ziprasidone hydrochloride)
    Publication number: 20050277651
    Abstract: The present invention relates to new and useful processes for the preparation of the anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride.
    Type: Application
    Filed: August 30, 2004
    Publication date: December 15, 2005
    Inventors: Carlos Zetina-Rocha, Allan Rey, Stephen Horne
  • Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1, 3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same
    Publication number: 20050256139
    Abstract: The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and preparations thereof.
    Type: Application
    Filed: July 7, 2004
    Publication date: November 17, 2005
    Inventors: Carlos Zetina-Rocha, Allan Rey, Matthew Buck, Lotfi Derdour, Stephen Horne, Keshava Murthy